Clinical Trial Update: A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects [Phase 1]

View source ↗

Summary

A Phase 1, double-blind, escalating-dose, randomized, placebo-controlled study in non-ambulant Duchenne muscular dystrophy patients evaluating pharmacokinetics,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Snippet

Sponsor: GlaxoSmithKline | Conditions: Muscular Dystrophies | Phase 1 | Status: COMPLETED